These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 11504978)

  • 21. Prevalence of transmitted nucleoside analogue-resistant HIV-1 strains and pre-existing mutations in pol reverse transcriptase and protease region: outcome after treatment in recently infected individuals.
    Balotta C; Berlusconi A; Pan A; Violin M; Riva C; Colombo MC; Gori A; Papagno L; Corvasce S; Mazzucchelli R; Facchi G; Velleca R; Saporetti G; Galli M; Rusconi S; Moroni M
    Antivir Ther; 2000 Mar; 5(1):7-14. PubMed ID: 10846586
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Prevalence of HIV-1 resistant to antiretroviral drugs in 81 individuals newly infected by sexual contact or injecting drug use. Investigators of the Quebec Primary Infection Study.
    Salomon H; Wainberg MA; Brenner B; Quan Y; Rouleau D; Coté P; LeBlanc R; Lefebvre E; Spira B; Tsoukas C; Sekaly RP; Conway B; Mayers D; Routy JP
    AIDS; 2000 Jan; 14(2):F17-23. PubMed ID: 10708278
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Reduced antiretroviral drug susceptibility among patients with primary HIV infection.
    Little SJ; Daar ES; D'Aquila RT; Keiser PH; Connick E; Whitcomb JM; Hellmann NS; Petropoulos CJ; Sutton L; Pitt JA; Rosenberg ES; Koup RA; Walker BD; Richman DD
    JAMA; 1999 Sep 22-29; 282(12):1142-9. PubMed ID: 10501117
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Thymidine analog and multinucleoside resistance mutations are associated with decreased phenotypic susceptibility to stavudine in HIV type 1 isolated from zidovudine-naive patients experiencing viremia on stavudine-containing regimens.
    Ross L; Scarsella A; Raffanti S; Henry K; Becker S; Fisher R; Liao Q; Hirani A; Graham N; St Clair M; Hernandez J;
    AIDS Res Hum Retroviruses; 2001 Aug; 17(12):1107-15. PubMed ID: 11522180
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The relation between baseline HIV drug resistance and response to antiretroviral therapy: re-analysis of retrospective and prospective studies using a standardized data analysis plan.
    DeGruttola V; Dix L; D'Aquila R; Holder D; Phillips A; Ait-Khaled M; Baxter J; Clevenbergh P; Hammer S; Harrigan R; Katzenstein D; Lanier R; Miller M; Para M; Yerly S; Zolopa A; Murray J; Patick A; Miller V; Castillo S; Pedneault L; Mellors J
    Antivir Ther; 2000 Mar; 5(1):41-8. PubMed ID: 10846592
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Impact of genotypic resistance testing on selection of salvage regimen in clinical practice.
    Haupts S; Ledergerber B; Böni J; Schüpbach J; Kronenberg A; Opravil M; Flepp M; Speck RF; Grube C; Rentsch K; Weber R; Günthard HF;
    Antivir Ther; 2003 Oct; 8(5):443-54. PubMed ID: 14640392
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Accuracy, precision, and consistency of expert HIV type 1 genotype interpretation: an international comparison (The GUESS Study).
    Zolopa AR; Lazzeroni LC; Rinehart A; Vezinet FB; Clavel F; Collier A; Conway B; Gulick RM; Holodniy M; Perno CF; Shafer RW; Richman DD; Wainberg MA; Kuritzkes DR
    Clin Infect Dis; 2005 Jul; 41(1):92-9. PubMed ID: 15937768
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Time trends in primary HIV-1 drug resistance among recently infected persons.
    Grant RM; Hecht FM; Warmerdam M; Liu L; Liegler T; Petropoulos CJ; Hellmann NS; Chesney M; Busch MP; Kahn JO
    JAMA; 2002 Jul; 288(2):181-8. PubMed ID: 12095382
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Persisting long-term benefit of genotype-guided treatment for HIV-infected patients failing HAART. The Viradapt Study: week 48 follow-up.
    Clevenbergh P; Durant J; Halfon P; del Giudice P; Mondain V; Montagne N; Schapiro JM; Boucher CA; Dellamonica P
    Antivir Ther; 2000 Mar; 5(1):65-70. PubMed ID: 10846595
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Drug-resistant reverse transcriptase genotyping and phenotyping of B and non-B subtypes (F and A) of human immunodeficiency virus type I found in Brazilian patients failing HAART.
    Caride E; Brindeiro R; Hertogs K; Larder B; Dehertogh P; Machado E; de Sá CA; Eyer-Silva WA; Sion FS; Passioni LF; Menezes JA; Calazans AR; Tanuri A
    Virology; 2000 Sep; 275(1):107-15. PubMed ID: 11017792
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Phenotypic or genotypic resistance testing for choosing antiretroviral therapy after treatment failure: a randomized trial.
    Meynard JL; Vray M; Morand-Joubert L; Race E; Descamps D; Peytavin G; Matheron S; Lamotte C; Guiramand S; Costagliola D; Brun-Vézinet F; Clavel F; Girard PM;
    AIDS; 2002 Mar; 16(5):727-36. PubMed ID: 11964529
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Antiretroviral drug resistance testing in adults with HIV infection: implications for clinical management. International AIDS Society--USA Panel.
    Hirsch MS; Conway B; D'Aquila RT; Johnson VA; Brun-Vézinet F; Clotet B; Demeter LM; Hammer SM; Jacobsen DM; Kuritzkes DR; Loveday C; Mellors JW; Vella S; Richman DD
    JAMA; 1998 Jun; 279(24):1984-91. PubMed ID: 9643863
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Clinical monitoring of HIV-1 infection in the ERA of antiretroviral resistance testing.
    Kartsonis NA; D'Aquila RT
    Infect Dis Clin North Am; 2000 Dec; 14(4):879-99. PubMed ID: 11144643
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Interpretation of resistance assay results.
    Miller V
    Antivir Ther; 2001; 6 Suppl 2():1-9. PubMed ID: 11678473
    [No Abstract]   [Full Text] [Related]  

  • 35. Utility of repeat genotypic resistance testing and clinical response in patients with three class resistance and virologic treatment failure.
    Badri SM; Adeyemi OM; Max BE; Hota BN; Barker DE
    AIDS Patient Care STDS; 2007 Aug; 21(8):544-50. PubMed ID: 17711379
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Study on mutations and antiretroviral therapy (SMART): preliminary results.
    Gianotti N; Moretti F; Tambussi G; Racca S; Presi S; Crucianelli R; Carrera P; Ferrari M; Lazzarin A
    Antivir Ther; 1999; 4 Suppl 3():65-9. PubMed ID: 16021873
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Modest decreases in NNRTI susceptibility do not influence virological outcome in patients receiving initial NNRTI-containing triple therapy.
    Harrigan PR; Hertogs K; Verbiest W; Larder B; Yip B; Brumme ZL; Alexander C; Tilley J; O'Shaughnessy MV; Montaner JS
    Antivir Ther; 2003 Oct; 8(5):395-402. PubMed ID: 14640386
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Evolving patterns of HIV-1 resistance to antiretroviral agents in newly infected individuals.
    Simon V; Vanderhoeven J; Hurley A; Ramratnam B; Louie M; Dawson K; Parkin N; Boden D; Markowitz M
    AIDS; 2002 Jul; 16(11):1511-9. PubMed ID: 12131189
    [TBL] [Abstract][Full Text] [Related]  

  • 39. HIV type 1 genotypic resistance in a clinical database correlates with antiretroviral utilization.
    Kagan R; Winters M; Merigan T; Heseltine P
    AIDS Res Hum Retroviruses; 2004 Jan; 20(1):1-9. PubMed ID: 15000693
    [TBL] [Abstract][Full Text] [Related]  

  • 40. In vivo emergence of drug-resistant mutations at less than 50 HIV-1 RNA copies/mL that are maintained at viral rebound in longitudinal plasma samples from human immunodeficiency virus type-1-infected patients on highly active antiretroviral therapy.
    Elbeik T; Hoo BS; Campodonico ME; Dileanis J; Fay FF; Bortolozzi RL; Benetti MS; Fay OH; Marlowe N; Petrauskene O; Chernoff D; Smith L; Ng VL
    J Hum Virol; 2001; 4(6):317-28. PubMed ID: 12082398
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.